Top

Published in:

01-02-2022 | Clinical study

Nivolumab plus ipilimumab: fewer AEs with lower dose ipilimumab

Published in: Reactions Weekly | Issue 1/2022

Excerpt

Fewer adverse events (AEs) are reported during treatment with nivolumab plus ipilimumab when the dosages are 3 mg/kg and 1 mg/kg, respectively (N3I1), than when the dosages are 1 mg/kg and 3 mg/kg, respectively (N1I3), according to findings of a systematic review and meta-analysis published in Therapeutic Advances in Medical Oncology. …

immune checkpoint inhibitor

Somekawa K, et al. Adverse events induced by nivolumab and ipilimumab combination regimens Therapeutic Advances in Medical Oncology : 11 Feb 2022. Available from: URL: https://doi.org/10.1177/17588359211058393

Title: Nivolumab plus ipilimumab: fewer AEs with lower dose ipilimumab
Publication date: 01-02-2022
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-10432-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Nivolumab plus ipilimumab: fewer AEs with lower dose ipilimumab

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Antibacterials

Antiglaucomas/nepafenac

Gemcitabine/paclitaxel

Infliximab/rituximab

Mycophenolate mofetil/prednisone/sirolimus

Bupivacaine/fentanyl/lidocaine